With another FDA nod, Eagle's Pemfexy gets up to speed with Lilly's Alimta

After gaining a tentative FDA approval for Pemfexy in 2017, it took nearly five years for Eagle Pharmaceuticals to bring the chemotherapy to the market because of a patent squabble with Eli Lilly.

It finally became available in February of this year for non-squamous non-small cell lung cancer (NSCLC) and mesothelioma patients.